Triple therapy in COPD: Oportunities and challenges

Marc Miravitlles (Barcelona, Spain)

Source: Short Video Statement 2020
Number: 1
Disease area: Airway diseases


Rating: 4.5
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Marc Miravitlles (Barcelona, Spain). Triple therapy in COPD: Oportunities and challenges. Short Video Statement 2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

Ioannis Karampinis - 28.10.2020 11:13
Well presented. I liked the addition of the flipboard, well done!
You must Login to comment this presentation.

Related content which might interest you:
What is the scientific and clinical rationale? Triple therapy in COPD patients
Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what?
Year: 2021

Triple therapy in COPD: only for the right patient
Source: Eur Respir J, 53 (4) 1900394; 10.1183/13993003.00394-2019
Year: 2019

Triple therapy trials in COPD: a precision medicine opportunity
Source: Eur Respir J, 52 (6) 1801848; 10.1183/13993003.01848-2018
Year: 2018

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
Source: ERJ Open Res, 5 (1) 00185-2018; 10.1183/23120541.00185-2018
Year: 2019

Treatment of COPD: from pharmacological to instrumental therapies
Source: Eur Respir Rev 2009; 19: 7-23
Year: 2010

Improving symptomology in COPD: which therapy would you choose, a brochodilator or pulmonary rehabilitation?
Source: International Congress 2019 – Hot topics in pulmonary rehabilitation
Year: 2019

Combination therapy versus separate therapy in real-life primary care asthma patients
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015

LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
Source: ERJ Open Res, 4 (4) 00047-2018; 10.1183/23120541.00047-2018
Year: 2018

Optimising bronchodilator therapy in COPD: Who, why and when?
Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care
Year: 2019

The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
Source: Breathe, 14 (4) 333; 10.1183/20734735.026418
Year: 2018

Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis
Source: Eur Respir J, 52 (6) 1801586; 10.1183/13993003.01586-2018
Year: 2018

Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020

Inhaled treatment of COPD: A delphi consensus statement
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016

The future of COPD treatment: what are the difficulties in and barriers to drug development for COPD
Source: Annual Congress 2011 - Lancet / ERS symposium - New frontiers in COPD
Year: 2011

The healthcare burden of non-compliance to pharmacotherapeutic escalation recommendations for COPD
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016

COPD - Current challenges
Source: Research Seminar 2009 - Post Genome Respiratory Epidemiology II - An interdisciplinary challenge
Year: 2008

Therapeutic options for COPD exacerbations
Source: International Congress 2014 – PG04 Update on COPD exacerbations
Year: 2014